Bronchogen Mucociliary Clearance Supplier

Sourcing Bronchogen for Mucociliary Clearance Research

Bronchogen is a synthetic tetrapeptide evaluated in preclinical models for its capacity to modulate bronchial epithelial cell expression, ciliary beat frequency, and mucociliary clearance mechanisms. Sourcing research-grade Bronchogen from PX1 Research guarantees lot-specific RP-HPLC purity >98%, mass spectrometry validation, low endotoxin levels, and US-manufactured stability for quantitative in vitro and animal assays.

In respiratory physiology research, mucociliary clearance serves as a primary innate defense mechanism of the upper and lower airways. Investigating candidate molecules that influence epithelial cell differentiation, mucin production, and ciliary transport requires highly purified research compounds. Laboratories seeking a reliable bronchogen mucociliary clearance supplier require fully characterized compounds that eliminate confounding variables such as endotoxin contamination, TFA residual toxicity, or synthesis impurities.

As a specialized US-based supplier of research peptides, PX1 Research provides academic, private, and institutional laboratories with fully validated Bronchogen reagents. Each batch undergoes rigorous analytical screening to support reproducible, high-resolution scientific data.

Molecular Profile and Biochemical Structure of Bronchogen

Bronchogen is a synthetic peptide bioregulator comprised of four amino acid residues: L-alanyl-L-glutamyl-L-aspartyl-L-leucine (sequence: Ala-Glu-Asp-Leu, or AEDL). Belonging to the class of short-chain peptides originally pioneered in peptide bioregulation studies, Bronchogen is designed to interact with targeted chromatin regions and nuclear structures in bronchial epithelial tissue.

The molecular weight of Bronchogen is approximately 460.45 g/mol, featuring an acidic peptide profile due to the side-chain carboxyl groups of glutamic acid (Glu) and aspartic acid (Asp). This specific side-chain configuration governs its solubility profile, ionic interactions, and binding affinity with target nuclear proteins or cell surface receptors in experimental models.

When sourcing Bronchogen for laboratory applications, structural verification via Electrospray Ionization Mass Spectrometry (ESI-MS) is critical. PX1 Research verifies the exact molecular mass and sequence integrity of every production lot to ensure researchers receive structurally authentic material free from truncated sequences or deletion peptides.

Proposed Mechanisms of Action in Pulmonary and Epithelial Models

Preclinical investigations indicate that short-chain peptide bioregulators like Bronchogen penetrate cellular and nuclear membranes to interact directly with specific DNA sequences. In vitro assays using primary bronchial epithelial cultures suggest that Bronchogen may modulate gene expression patterns involved in cellular differentiation, protein synthesis, and structural tissue maintenance.

Mucociliary clearance depends on the coordinated activity of ciliated epithelial cells and the balance of gel and sol mucus layers produced by goblet cells and submucosal glands. Research models evaluating respiratory epithelial stress indicate that Bronchogen exposure may influence:

• Ciliary Beat Frequency (CBF): In vitro recordings in airway epithelial explants suggest potential maintenance or restoration of synchronized ciliary beat patterns following toxic or oxidative insult. • Mucin Gene Regulation: Gene expression profiling in rodent models indicates alterations in MUC5AC and MUC5B transcript levels, which regulate mucosal viscoelasticity. • Inflammatory Cytokine Modulation: Cellular assays demonstrate shifts in pro-inflammatory signals (such as IL-6, IL-8, and TNF-alpha) when bronchial tissue explants are incubated with short-chain synthetic peptides. • Epithelial Barrier Integrity: Trans-epithelial electrical resistance (TEER) measurements in air-liquid interface (ALI) cultures indicate potential structural reinforcement of tight junction proteins (ZO-1, occludin).

Preclinical Literature Review: Mucociliary Dynamics and Tissue Assays

The scientific literature surrounding short-chain pulmonary peptides focuses heavily on age-related, toxicant-induced, or pathogen-exposed bronchial models. In rodent models subjected to chronic smoke exposure or inflammatory challenge, administration of peptide bioregulators demonstrated a preservation of ciliated cell density and decreased epithelial desquamation compared to non-treated control groups.

In vitro data indicate that primary human bronchial epithelial cells (HBECs) cultured at the air-liquid interface retain differentiated morphological characteristics for longer durations when exposed to peptide bioregulators in the growth medium. Researchers tracking mucociliary transport rates using fluorescent microbead assays have reported measurable shifts in particle clearance velocity across the mucosal surface.

These observations highlight Bronchogen's utility as a tool for studying fundamental pulmonary cell biology. Investigators utilize this compound to dissect the downstream signaling cascades responsible for respiratory repair, airway remodeling, and mucociliary clearance homeostasis. Comprehensive analytical reviews and citations can be explored within the PX1 research library.

Comparative Analysis: Bronchogen vs. Other Bioregulatory Peptides

To contextualize Bronchogen within peptide research, investigators frequently evaluate it alongside other short-chain bioregulators and tissue repair molecules. Understanding the structural and tissue-specific differences between these compounds allows researchers to select the precise reagent for their experimental paradigm.

While Bronchogen (Ala-Glu-Asp-Leu) exhibits specific activity toward bronchial epithelial systems, other synthetic peptides target distinct tissue pathways. For example, Vilon (Lys-Glu) is a dipeptide primarily studied for its generalized immunomodulatory and chromatin-activating properties across broad connective tissue models. In contrast, Epitalon (Ala-Glu-Asp-Gly) targets pineal function and telomerase expression in aging models.

For broader systemic tissue recovery models, investigators often compare Bronchogen with localized cell-repair peptides such as BPC-157. While BPC-157 acts largely via angiogenic pathways and growth factor upregulation (such as VEGF and FAK), Bronchogen's mechanism is specifically linked to nuclear interactions and epithelial gene regulation within airway cellular structures. Detailed comparative overviews are documented in our guide to short-chain Khavinson bioregulators.

Analytical Quality Standards for Research-Grade Bronchogen

Evaluating a supplier for research-grade peptides requires reviewing robust, unedited analytical documentation. Because subtle impurities or trace contaminants can alter cellular responses in sensitive mucociliary assays, PX1 Research enforces a stringent multi-tier testing protocol for every lot of Bronchogen.

High-Performance Liquid Chromatography (RP-HPLC): Reverse-phase HPLC is employed to quantify chromatographic purity. PX1 Research mandates a minimum purity threshold of >98%, ensuring that synthesis side-products, unreacted amino acids, and truncated peptides are minimized.

Mass Spectrometry (ESI-MS): Mass spectrometry confirms the precise molecular weight and identity of the synthetic peptide. The resulting spectra verify that no incorrect sequence insertions or unexpected adducts exist in the final lyophilized product.

Endotoxin Screening (LAL Assay): Bacterial endotoxins (lipopolysaccharides) alter immune responses in bronchial cell cultures and animal models, confounding experimental outcomes. PX1 Research tests every lot using Chromogenic Limulus Amebocyte Lysate (LAL) assays to verify endotoxin levels below 0.01 EU/mg, meeting the strict standards required for cell culture and in vivo preclinical protocols.

All analytical testing is executed by ISO 17025 accredited, independent third-party laboratories within the United States. Certificate of Analysis (COA) documents featuring raw HPLC chromatograms and mass spectra are available for transparent verification.

Laboratory Reconstitution Protocols and Handling Guidance

Achieving reproducible experimental results requires proper reconstitution and handling of lyophilized Bronchogen. Researchers must adhere to standard aseptic technique inside a certified biosafety cabinet (BSC) to prevent microbiological contamination.

1. Solvent Selection: Bronchogen exhibits high solubility in aqueous buffer systems. Recommended reconstitution vehicles include sterile Bacteriostatic Water (0.9% benzyl alcohol), Sterile Water for Injection (SWFI), or sterile Phosphate-Buffered Saline (PBS, pH 7.4) depending on the experimental assay.

2. Reconstitution Process: Equilibrate the glass vial to room temperature before reconstitution to prevent moisture condensation. Introduce the desired volume of diluent gently along the inner glass wall of the vial. Allow the solid matrix to dissolve naturally, or apply gentle swiveling. Avoid vigorous vortexing or rapid agitation, which can induce physical shear stress and peptide aggregation.

3. Working Concentration: For in vitro cell culture applications, working stock solutions are typically prepared at concentrations ranging from 1 mg/mL to 10 mg/mL, which can then be serially diluted into cell culture media according to protocol specifications.

Storage, Stability, and Lyophilization Integrity

Peptides are sensitive to thermal degradation, hydrolysis, and photo-oxidation. Proper laboratory storage protocols preserve structural integrity and maintain product shelf-life.

• Lyophilized Powder: Store sealed vials in a commercial freezer at -20°C (or -80°C for long-term storage exceeding 12 months). Keep vials protected from light exposure in desiccated environments. • Reconstituted Solutions: Once reconstituted in liquid media or sterile buffer, store stock aliquots at 2°C to 8°C for short-term use (up to 7 days). For extended storage of liquid stock, divide into single-use micro-centrifuge tubes and freeze at -20°C or colder to avoid repeated freeze-thaw cycles.

Repeated freezing and thawing of liquid peptide solutions can cause physical degradation and precipitation, compromising accurate concentration metering in quantitative research assays.

Procuring High-Purity Bronchogen from PX1 Research

PX1 Research is committed to supplying domestic laboratories with reliable, fully documented research compounds. All peptides in our catalog are manufactured in the United States within state-of-the-art facilities compliant with Good Manufacturing Practice (GMP) standards.

Orders placed Monday through Friday ship same-day from our strategically located dispatch centers in California and Arizona, minimizing transit times and cold-chain disruption. Vials are packaged securely to prevent mechanical damage during transport.

Institutional buyers, academic departments, and commercial laboratories requiring bulk quantities or recurring order schedules can establish a dedicated wholesale laboratory account to access specialized pricing and lot-reservation services.